Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 40/100

Failure Rate

14.3%

1 terminated/withdrawn out of 7 trials

Success Rate

85.7%

-0.8% vs industry average

Late-Stage Pipeline

0 trials in Phase 3/4

Results Transparency

100%

6 of 6 completed trials have results

Key Signals

6 with results

Enrollment Performance

Analytics

Phase 2

4(57.1%)

Phase 1

3(42.9%)

7Total

Phase 2(4)

Phase 1(3)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (7)

Showing 7 of 7 trials

NCT01339052Phase 2Completed

Phase II Study of BKM120 for Subjects With Recurrent Glioblastoma

Role: lead

NCT00441142Phase 1Completed

Zactima With Temodar During Radiation Treatment for Newly Diagnosed Stage IV Brain Tumors

Role: lead

NCT01339039Phase 1Terminated

Plerixafor (AMD3100) and Bevacizumab for Recurrent High-Grade Glioma

Role: lead

NCT00859040Phase 2Completed

Monthly SOM230C for Recurrent or Progressive Meningioma

Role: lead

NCT00859222Phase 1Completed

LBH589 and Bevacizumab in Patients With Recurrent High Grade Glioma

Role: lead

NCT01380782Phase 2Completed

BIBF 1120 for Recurrent High-Grade Gliomas

Role: lead

NCT00657267Phase 2Completed

Dose-Intense Temozolomide in Recurrent Glioblastoma

Role: lead

All 7 trials loaded